On May 27, 2020, ADVANZ PHARMA Corp. Limited ("ADVANZ") announced the completion of its plan of arrangement (the "Arrangement") with specialty pharmaceutical company Correvio Pharma Corp. ("Correvio"). Pursuant to the Arrangement, ADVANZ, through a wholly-owned subsidiary, acquired all of the issued and outstanding common shares of Correvio for US$0.42 in cash consideration per share, valuing Correvio’s equity at approximately US$28 million on a fully diluted basis. The acquisition had a total purchase price of approximately US$76 million, which included the repayment of certain Correvio indebtedness.
Client Work
ADVANZ PHARMA Corp. Limited in its U$76 million acquisition of Correvio Pharma Corp.
Fasken
Reading Time
1 minute read
Overview
Overview
Team
Team
- John M. Sabetti, Partner, Toronto, ON, +1 416 865 4455, jsabetti@fasken.com
- Richard J. Steinberg, Partner, Toronto, ON, +1 416 865 5443, rsteinberg@fasken.com
- Aaron J. Stefan, Partner, Toronto, ON, +1 416 868 3514, astefan@fasken.com
- Gurinder (Gigi) Gujral, Associate, Toronto, ON, +1 416 868 3431, ggujral@fasken.com
- Jackie VanDerMeulen, Partner, Toronto, ON, +1 416 865 5402, jvandermeulen@fasken.com
- Justine Connors, Partner, Toronto, ON, +1 416 868 7530, jconnors@fasken.com
- Mark Pontin, Partner, Vancouver, BC, +1 604 631 4932, mpontin@fasken.com
- Rachel Phillips, Partner, Toronto, ON, +1 416 865 5154, rphillips@fasken.com
- Robin Spillette, Associate, Toronto, ON, +1 416 868 7817, rspillette@fasken.com
- George Soules, Associate, Toronto, ON, +1 416 868 7810, gsoules@fasken.com
